DUBLIN, Ireland & BURLINGAME, Calif.--(BUSINESS WIRE)--ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 myeloid checkpoint mechanism, today announced that Jaume Pons, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 4:00 p.m. ET at the Grand Hyatt in New York, NY.
About ALX Oncology
ALX Oncology is a clinical-stage
immuno-oncology company developing therapies that block the CD47
checkpoint mechanism, which is exploited by cancer cells to evade the
immune system. Our lead candidate, ALX148, is a fusion protein comprised
of an engineered high affinity CD47 binding domain of SIRPĪ± linked to an
inactive Fc region of human immunoglobulin. ALX148 is designed to
maximize the clinical benefit of antibody-based therapies and is in
clinical development for a broad range of tumor types. www.alxoncology.com